Richard A. Larson to Neoadjuvant Therapy
This is a "connection" page, showing publications Richard A. Larson has written about Neoadjuvant Therapy.
Connection Strength
0.023
-
Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood. 2014 Feb 27; 123(9):1353-60.
Score: 0.023